Therapeutic Goods (Standard for Medicinal Cannabis) (TGO 93) Order 2017

The order’s central organising concepts are product scope, active-ingredient definition, source fidelity, identity testing, contaminant limits, manufacturing quality assurance (including extraterritorial sites), labelling and packaging, microbiological quality, and transitional timing.

Scope and application. The order applies to “medicinal cannabis products” and to “any ingredients used in the manufacture of those products, including, but not limited to, the cannabis plant” (s 6(1)). It excludes certain categories: export-only medicines, items expressly listed in Schedule 5 to the Regulations, and particular items in Schedule 5A subject to their conditions (s 6(2)). The standard is expressly declared to be a standard under the Therapeutic Goods Act (s 5), so compliance is treated as compliance with that standard within the statutory regulatory regime.

Active-ingredient thresholds and source. The order defines active ingredient as in the Regulations but supplements that by prescribing when cannabinoids count as active ingredients for the order’s purposes: THC (and any corresponding acid) at or above 1.0% w/w or w/v, and any other cannabinoid (and its acid) at or above 2.0% w/w or w/v (s 4(2)). The order requires that each active ingredient and any other cannabinoid not treated as an active ingredient must be from the cannabis plant and must not be chemically or otherwise modified or transformed, except that decarboxylation of natural acid forms is not considered a modification (s 8 and note).

Identity and anti-adulteration. Cannabis plants used in manufacture must be positively identified by macroscopic, microscopic and chromatographic methods (s 10). Adulteration is prohibited; the order defines adulteration to include addition or substitution of any substance extraneous to the formulation other than a processing aid, and says intent or motive to improve, fortify or debase is irrelevant to the determination (s 11).

Manufacturing quality and overseas manufacture. The order requires that manufacturing steps occurring outside Australia comply with a specified list of good manufacturing practice (GMP) standards or equivalents (s 13(2)). For products manufactured overseas, the manufacturing site must have a valid GMP certificate or other listed documentary confirmation, and those documents must cover the specific product and each manufacturing site and be current at the time of manufacture (s 13(3)-(4)). The instrument specifies country-specific documentary options (United Kingdom, EU Member States, Canada, South Africa, Israel, New Zealand) and a fallback requiring written TGA confirmation of conformity with the PIC/S Guide to GMP for other countries (s 13(3)(a)-(f), (ea)).

Testing, assay and contaminant limits. Schedule 1, adopted by s 12(1), prescribes tests (Ph Eur test methods) and numeric limits for aflatoxins, foreign matter, heavy metals (arsenic, cadmium, lead, mercury), ochratoxin A, pesticides (subject to Ph Eur limits), and total ash. Section 12(2) sets assay limits for active-ingredient content varying by dosage form: herbal final form 80-120% of stated content; unregistered tablets or capsules 90-110% for pooled samples; other dosage forms 90-110%. For registered tablets/capsules, a different standard (TGO 101) applies (s 12(2) note).

Packaging and labelling. Child-resistant packaging requirements are incorporated by reference to TGO 95 for relevant products (s 14). Labelling obligations for finished products are comprehensive: product name, sponsor contact details, storage conditions, batch number (with prescribed prefix forms), expiry date (with prescribed prefix forms and exclusions such as “Best by”), active ingredient names and quantities, dosage form, and quantity (s 15(2)). Additional mandatory information for plant preparations and plant material is specified (s 15(2)(g)-(h)). Labels must be in English, legible, visible, not obscured and durable (s 15(4)).

Microbiological criteria. Oral and inhalation products must meet the microbiological acceptance criteria of one of the British Pharmacopoeia, European Pharmacopoeia, USP-NF, or a special Ph Eur provision for natural raw materials for which antimicrobial pre-treatment is not feasible (s 16). The order specifies the test methods to accompany each acceptance-criteria option (s 16(a)-(d)).

Transitional application. Sections 13-16 apply only to products released for supply on or after 1 July 2023 (s 17), which creates a temporal compliance requirement affecting existing stock and supply chains.

Taken together, these concepts create a layered compliance regime: input controls (source fidelity, testing), process controls (GMP documentary requirements and identity tests), output controls (assay ranges, contaminant limits, microbiological criteria), and consumer-facing controls (labelling, packaging). The order relies heavily on imported pharmacopoeial specifications and recognised GMP frameworks to define technical standards, and delegates to documentary proof and testing to demonstrate compliance.

The order allocates obligations and verification duties primarily to sponsors and manufacturers of medicinal cannabis products, and secondarily to overseas manufacturing sites, testing laboratories and, indirectly, pharmacists and dispensers in the context of extemporaneous compounding.

Sponsors. The label and distribution responsibilities fall squarely on the sponsor. Section 4(1) notes that “sponsor” is defined in the Act’s subsection 3(1); s 15(2)(b) requires the sponsor’s name and contact details to be on the finished product label. Sponsors are therefore the primary domestic actors required to ensure that a product released for supply in Australia complies with labelling (s 15), packaging (s 14), assay limits (s 12), contaminant tests (Schedule 1), microbiological criteria (s 16), and that adequate documentation exists for any overseas stages of manufacture (s 13(3)-(4)).

Manufacturers and manufacturing sites. Manufacturers both in Australia and overseas must meet the manufacturing quality and GMP-linked documentary regime. Section 13(2) prescribes which GMP standards must be followed for steps conducted outside Australia. Section 13(3) requires that a site manufacturing a medicinal cannabis product outside Australia be the subject of specific certificates, licences or written confirmations depending on country of manufacture; those documents must cover the relevant product and each manufacturing site and be current when the product was manufactured (s 13(4)). The order therefore affects overseas manufacturers and requires sponsors to obtain and retain proof of compliance from those sites.

Testing laboratories. The order demands particular tests and test methods (Schedule 1, s 12(1) and s 16). Laboratories performing identity, assay, contaminant and microbiological testing must be able to execute the referenced Ph Eur, BP or USP-NF methods. The order also specifies that most Schedule 1 limits apply on a dried basis (Schedule 1(1) and note), which affects sample preparation and laboratory protocols.

Pharmacists compounding for individual patients. The order treats extemporaneously compounded or repackaged medicinal cannabis products differently: labels must state the name and quantity of each active ingredient purported to be present (s 15(3)). Pharmacists who compound patient-specific products must therefore follow the labelling obligation and be aware that other labeling and possibly manufacturing provisions may not apply to their compounding, depending on the details of the product and the Act/Regulations (s 15(3) qualification).

Importers and sponsors of foreign products. Sponsors who import products or source from overseas manufacturers must secure GMP certificates, licences or written confirmations that (a) cover the product and each manufacturing site, and (b) were current at the time of manufacture (s 13(3)-(4)). For products manufactured in countries not specifically listed (for example, countries other than the UK, EU Member States, Canada, South Africa, Israel or New Zealand), the sponsor must secure written confirmation from the Therapeutic Goods Administration that the site operates in accordance with the PIC/S Guide to GMP (s 13(3)(f)).

Consumers and healthcare professionals. While the order does not directly regulate prescribing decisions, it affects the composition, labelling and quality of products that prescribers, dispensers and patients encounter. The label requirements (s 15) shape the information available at point of supply, and the packaging requirements (s 14) shape how products are presented to patients. Microbiological and contaminant limits affect product safety profiles.

Regulators. The Therapeutic Goods Administration, as referenced by the order’s use of “Secretary” in the definitions and the requirement for TGA confirmations in certain circumstances (s 4 notes and s 13(3)(c)(i)(B), (ea)(iii), (f)), is the decision-maker for certification recognition and for issuing the written confirmations required by the order. The order places on the TGA the function of verifying documentary conformity for non-Australian manufacturing sites and for non-listed countries.

Who bears costs and administrative burden. Sponsors and manufacturers bear the direct compliance costs: testing (identity, assay, contaminants, microbiological), additional labelling and packaging changes (including child-resistant packaging when applicable, s 14), obtaining and maintaining GMP certificates and licences, and replacing certain decontamination techniques (s 9). Overseas manufacturers must either obtain recognitions (certificates/licences) or secure TGA confirmation (s 13(3)), and sponsors must procure and retain documentary proof that covers product and site and is current at manufacture (s 13(4)). Testing laboratories may incur costs to implement or maintain the specific pharmacopeial test methods referenced.

Who decides. The order prescribes technical standards and documentary thresholds. The TGA decides whether documentary confirmations or certificates satisfy s 13 requirements where TGA confirmation is explicitly required. Sponsors decide on suppliers and manufacturing sites, and must decide whether a cannabinoid meets the active-ingredient thresholds in s 4(2) and therefore whether the product must be labelled and tested accordingly (s 15, s 12). Manufacturers decide process steps such as decontamination methods subject to the prohibition on ethylene oxide (s 9) and must implement identity testing methods (s 10).

In short, the order affects the full supply chain from cultivators of cannabis plant material through overseas and domestic manufacturers, testing laboratories, sponsors, pharmacists who compound for patients, and the TGA as the certifying authority for overseas manufacturing conformity. The primary burdens fall on sponsors and manufacturers to secure test data, maintain GMP documentation and ensure product labels and packaging meet the specified format and content requirements.

Duties are concentrated on sponsors and manufacturers, with specific procedural and documentary obligations. The order itself creates no standalone private rights or remedies; it sets technical and documentary standards which, once adopted into regulatory enforcement by the Therapeutic Goods Act regime, inform what the regulator will regard as compliant.

Mandatory duties (selected, with sections cited)

• Product scope and exclusions: Determine whether the product is within the order’s application (s 6). The order applies to medicinal cannabis products and ingredients used in their manufacture (s 6(1)) but excludes export-only medicines and certain Regulation Schedule items (s 6(2)).

• Source and integrity of cannabinoids: Ensure each active ingredient and any other cannabinoid is from the cannabis plant and is not chemically modified or transformed, save for decarboxylation of natural acid forms, which is explicitly not regarded as modification (s 8 and note).

• Decontamination: Refrain from any decontaminating treatment using ethylene oxide and ensure decontamination does not adversely affect product quality (s 9).

• Identification: Positive identification of cannabis plants used in manufacture by macroscopic examination, microscopic examination and chromatographic procedures (s 10).

• Anti-adulteration: Ensure no adulteration via addition or substitution of extraneous substances (processing aids excepted), with intent irrelevant (s 11).

• Testing and assay limits: Perform tests specified in Schedule 1 (s 12(1)) and ensure assay limits are within the specified ranges depending on dosage form (s 12(2)). For registered tablets/capsules, comply with TGO 101 assay limits (s 12(2) note).

• Manufacturing quality and documentary proof for overseas manufacture: If any manufacturing step occurs outside Australia, ensure compliance with one or more listed GMP regimes (s 13(2)); obtain and hold certificates/licences/written confirmations covering the product and each manufacturing site that were current when the product was manufactured (s 13(3)-(4)).

• Packaging: Comply with child-resistant packaging requirements by meeting the specified sections of TGO 95 for all products other than plant material and certain exceptions (s 14(1)-(2)).

• Labelling: For finished products (other than pharmacist-compounded for a particular patient), ensure labels include the mandatory items in s 15(2) and that label text is English, legible, visible, not obscured and durable (s 15(4)). For extemporaneous compounding by a pharmacist, label must state name and quantity of each active ingredient purported to be present (s 15(3)).

• Microbiological criteria: For oral dosage forms or inhalation products, ensure compliance with one of the prescribed pharmacopeial microbiological acceptance criteria and the associated testing methods (s 16).

Evidence and documentation duties. Sponsors must gather and retain documentary evidence: GMP certificates, licences, written confirmations, and test reports demonstrating compliance with Schedule 1 and s 16. Section 13(4) requires that the documentary instruments “cover the relevant medicinal cannabis product” and “relate to each manufacturing site where the medicinal cannabis product was manufactured” and “have been current at the time the medicinal cannabis product was manufactured.” Those are precise documentary thresholds.

Rights and decision-making levers (as implied in the order)

• Choice of recognized GMP pathway for overseas manufacture. For products manufactured outside Australia, the sponsor/manufacturer may elect which listed GMP standard or country-specific documentary pathway to follow, provided the documentary proof covers product and site and is current (s 13(2)-(3)). For manufacturers in Canada or New Zealand, the order provides alternative documentary pathways (s 13(3)(c), (ea)), so sponsors have options to select the most practicable route.

• Selection among microbiological standards. For oral and inhalation products, sponsors may choose among four acceptance-criteria frameworks (BP, Ph Eur, USP-NF, or the Ph Eur special provision) (s 16). Choosing one standard commits the sponsor to the specific testing methods tied to that standard (s 16(a)-(d)).

• Labelling options governed by content rules. Sponsors must include specified information and may adopt the prescribed prefixes for batch numbers and expiry dates (s 4(1) definitions, s 15(2)(d)-(e)). The order provides examples for plant preparations and plant materials, which guides label language (s 15(2)(g)-(h)).

• Use of processing aids. The order permits processing aids (as defined in s 4) to be used in manufacture, so long as they are not intended to remain in final formulation beyond trace amounts (s 4 definition of processing aid and s 11(2) which excepts processing aids from adulteration).

• Transitional timing. Sponsors can continue to supply products released before 1 July 2023 without those products being subject to s 13-16; the sections apply only to products released on or after that date (s 17). That gives companies time to adjust supply chains and documentation.

Allocation of decision authority. The order imposes technical duties on sponsors and manufacturers, while the Therapeutic Goods Administration is the decision authority for recognition of overseas GMP compliance where a written confirmation is required (s 13(3)(f), (ea)(iii)). The order refers to the Secretary’s decisions under s 25 and applications under s 19 of the Act in the definition of “stated content” (s 4(1) paragraphs under “stated content”), suggesting that the Secretary’s administrative decisions concerning approvals and notifications will be the mechanism through which certain label content and declared contents are fixed.

In combination, the order imposes granular procedural and documentary duties on commercial actors and grants them choices among alternative technical standards, while placing oversight and final recognition functions with the regulator.

The order itself does not set out specific penalties or criminal sanctions. It is made under the Therapeutic Goods Act 1989 (s 3) and “constitutes a standard for medicinal cannabis products” (s 5). Under the Act, standards established by orders are normally the benchmarks the regulator uses to determine compliance with statutory obligations under the Act and Regulations. The order therefore operates as a technical compliance yardstick; enforcement and penalties for non-compliance with those statutory obligations derive from the Act and Regulations rather than from the order’s text.

What the order specifies about enforcement mechanisms, as an instrument, is procedural and documentary. It prescribes documentary proof for manufacturing sites (s 13(3)-(4)), labelling and packaging content (s 14-15), and tests and limits (s 12, Schedule 1). Those prescriptions create measurable compliance criteria. Although the order does not enumerate enforcement tools, the practical enforcement pathway is that a product failing to meet the order’s standards will be non-compliant with the standard the TGA administers under the Act. Consequences within the Act’s framework commonly include regulatory actions such as refusal to register or list, product recalls, suspension of supply privileges, directions to remedy defects, and prosecution where statutory offences apply; however, the order does not itself state which of these measures will be applied.

Administrative discretion and evidence thresholds. The order requires documentary proof for overseas manufacturing sites and specific testing data. Section 13(4) makes documentary currency and product/site coverage a condition of compliance. This imposes evidential duties on sponsors: the absence, incompleteness or expiry of the required certificates/licences/written confirmations is a measurable non-compliance. The order therefore delegates a form of evidential gatekeeping to the sponsor and to the TGA when the TGA is asked to accept a written confirmation for sites in other countries (s 13(3)(f)).

Transitional enforcement. Sections 13, 14, 15 and 16 apply to products released for supply on or after 1 July 2023 (s 17). Enforcement posture for products released before that date is therefore governed by the prior applicable standard; the transitional provision limits the regulator’s ability to rely on s 13-16 for earlier supplies. That transitional rule reduces immediate enforcement pressure on existing inventories released prior to the effective date, but it also creates a deterministic date after which products must meet the stricter documentary, labelling, packaging and microbiological requirements.

Potential compliance failures the order identifies through obligations. The order defines a set of measurable failures: failure to obtain valid and current GMP certificates or written confirmations for overseas manufacturing sites that cover the relevant product and site at the time of manufacture (s 13(3)-(4)); presence of prohibited decontamination residues, such as ethylene oxide (s 9); inadequate label content or format (s 15); non-conforming child-resistant packaging where required (s 14); assay values outside the specified ranges (s 12(2)); microbiological criteria not met under the chosen pharmacopeial standard (s 16); and Schedule 1 contaminants exceeding numerical limits. Each of these failures will present straightforward documentary or analytical evidence for enforcement action under the Act.

Who enforces. The order repeatedly references the Therapeutic Goods Administration and the Secretary for documentary confirmations and decisions (for example s 4 definitions referencing Secretary decisions under s 25 of the Act and s 13(3)(c)(i)(B) and (ea)(iii) referencing written confirmation from the Therapeutic Goods Administration). Thus the TGA is the operational enforcement agency, tasked with interpreting whether documentary evidence and testing reports satisfy the order. The order places the responsibility on regulated parties to produce the documentation and results the TGA needs to reach its enforcement decisions.

Practical implication. Although the order does not itself prescribe fines or criminal penalties, it creates objective compliance thresholds which, when not met, leave the regulated product vulnerable to the enforcement powers the Act confers. Entities in the supply chain must therefore manage documentary and testing risks proactively to avoid enforcement outcomes under the Act and Regulations.

The order embeds and cross-references multiple pre-existing regulatory instruments and pharmacopoeial standards, and it operates within the broader Therapeutic Goods Act and Regulations framework. Its interactions are primarily by reference and by making compliance with external standards a condition of compliance with the order.

Therapeutic Goods Act 1989 and Regulations. The order is made under subsection 10(1) of the Act (s 3) and “constitutes a standard” under the Act (s 5). Definitions used in the order point directly to terms defined in subsection 3(1) of the Act (s 4, note). The order references the Regulations in the definition of “active ingredient” and in the exclusions to application (s 4 and s 6(2)). The order therefore functions as a subordinate instrument that sets technical standards within the Act’s regulatory architecture , compliance with this order will be assessed in the context of obligations and enforcement tools provided in the Act and Regulations.

Pharmacopoeia and international standards. The order imports several pharmacopeial monographs and test methods by reference:

• The European Pharmacopoeia Pharmaceutical Preparations (2619) monograph applies to medicinal cannabis products and ingredients, except to the extent of any inconsistency with this order (s 7). The monograph also incorporates other EU monographs such as Herbal Drugs (note in s 7).

• Schedule 1 specifies test methods from the Ph Eur (columns in Schedule 1 refer to Ph Eur test methods such as 2.8.18, 2.8.2, 2.4.27, 2.8.22, 2.8.13 and 2.4.16) and associated limits.

• Microbiological acceptance criteria options under s 16 include British Pharmacopoeia Appendix XVI D and methods in Appendix XVI B, the European Pharmacopoeia Microbiological Quality provisions and methods (2.6.12, 2.6.13), and the United States Pharmacopeia-National Formulary chapters <1111>, <61> and <62>. The order therefore requires parties to adopt internationally recognised pharmacopoeial standards and laboratory methods.

Other Therapeutic Goods Orders. The order incorporates or relies on other TGOs. For example, child-resistant packaging requirements refer to TGO 95, and registered tablet/capsule assay limits refer to TGO 101 (s 14(2) and s 12(2) note). This means compliance must be considered in the wider landscape of TGO obligations.

International regulatory frameworks and bilateral recognition. Section 13 maps overseas manufacturing recognition to specific national regulators and guides. For example, for manufacture in the UK or an EU Member State, the order requires a valid certificate of GMP issued by the MHRA or an EU licensing authority (s 13(3)(a)-(b)). For Canadian manufacture, either confirmation of compliance with Canada’s Part 5 Good Production Practices plus a valid EU GMP certificate or TGA confirmation of PIC/S GMP conformity is required, or alternatively a Drug Establishment Licence issued by Health Canada (s 13(3)(c)). For South Africa and Israel, written confirmation from those national regulators or a valid certificate is required (s 13(3)(d)-(e)). For New Zealand, several options are listed, including a Licence to Manufacture Medicines under the Medicines Act 1981 (NZ), a valid Medsafe GMP certificate, or TGA confirmation of PIC/S conformity (s 13(3)(ea)). For other countries, written TGA confirmation of conformity with PIC/S Guide to GMP is required (s 13(3)(f)). These cross-references create a web of bilateral regulatory recognition that affects importers and exporters.

Interaction with customs, quarantine and food laws. The order prescribes contaminant limits (heavy metals, pesticides, aflatoxins, ochratoxin A, total ash) and microbial criteria for oral/inhalation products. While the order does not mention customs or biosecurity law, products crossing borders and the agricultural inputs used may also be subject to customs, biosecurity and food-related controls; the order’s limits therefore interact with those enforcement regimes in practice, though only the text of this order and the Act are authoritative here.

Administrative decisions under the Act. The order’s definition of “stated content” refers to outcomes of decisions by the Secretary under s 25 of the Act, applications under s 19, and notifications under regulation 12A (s 4(1) “stated content” paragraphs). This ties labelling and declared content obligations back to specific administrative decisions and notifications under the Act and Regulations.

Transitional timing and pre-existing regulatory arrangements. Section 17 provides a temporal interaction: s 13-16 apply only to medicinal cannabis products released for supply on or after 1 July 2023. That means pre-existing stock released before that date remains governed by the regulatory standard that applied at the time of release, and regulatory compliance actions for those stocks must be assessed accordingly.

In sum, the order is not a self-contained regime; it is designed to operate as a technical standard embedded in a larger network of Australian statutory requirements, international pharmacopoeial standards, other TGOs, and country-specific GMP recognition arrangements. Compliance requires coordinated adherence to the order plus the referenced external instruments and the Act’s administrative framework.

The instrument identifies itself as the Therapeutic Goods (Standard for Medicinal Cannabis) (TGO 93) Order 2017 (s 1). The text provided contains internal references to documents and standards current as of specific dates (for example, PIC/S Guide to GMP dated 1 May 2021 is mentioned in the definition of PIC/S Guide to GMP in s 4). The order also contains provisions that refer to EU directives “as in force or existing from time to time” (for example, EU Directive 2001/83/EC and EU Directive 2003/94/EC in s 4 definitions and s 13(2)(b)-(c)) and references to documents “as in force or existing from time to time” for other international guides (for example, the New Zealand Code of GMP, South African Guide to GMP, and Canadian and US regulatory provisions in s 13(2)). These references indicate the order is designed to accommodate updates to external technical standards without text amendments to the order itself.

The text provided does not include an express schedule of amendments, amending instrument numbers or dates beyond its title year (2017) and the transitional date specified (s 17: 1 July 2023). No amending instruments or historical notes are included in the version supplied. Section 13(3)(ea) adds New Zealand options and its subitems reference the PIC/S confirmation option and Medsafe documents, which suggests that at least by the time the version provided was current the order had been drafted to include New Zealand-specific recognition pathways; however the instrument as given does not include an amendment history log.

Key temporal markers within the text:

• The order is titled TGO 93 Order 2017 (s 1), which records the instrument's origin year.

• References to external documents include dated editions or versions (for example PIC/S Guide to GMP PE 009-15, 1 May 2021 in s 4 definition), indicating reliance on particular versions for technical conformity.

• Transitional application: sections 13, 14, 15 and 16 apply to products released for supply in Australia on or after 1 July 2023 (s 17). This transitional clause is an internal timing amendment effect that delayed application of key production, labelling, packaging and microbiological obligations until that date.

Because the instrument text does not include a formal amending history, practitioners should consult the Federal Register of Legislation or TGA instrument registers for the authoritative instrument history, amendment instruments, commencement dates, and any disallowances or variations. The order repeatedly invokes external documents “as in force or existing from time to time,” which reduces the need for frequent textual amendments to the order when those external standards change, but it also requires users to track updates of those external documents for compliance.

Users should also note that the order’s cross-references to the Act and Regulations (for example, exclusions tied to Schedule 5 and Schedule 5A to the Regulations, and labelling content tied to Secretary decisions under s 25) mean that changes to the Act, Regulations or to other TGOs (TGO 95, TGO 101) will materially affect the operational compliance framework. Any amendments to those instruments,or to the listed international standards, GMP guides or pharmacopoeial monographs,may therefore change compliance obligations without an amendment to this order itself.

In short, the instrument supplies no amendment log in the text provided; its effective changes are signalled by the instrument date (2017), the PIC/S guide citation date (2021), and the internal transitional commencement date of 1 July 2023 (s 17). For precise amendment lineage, readers should consult the formal legislative register.

The order’s text contains no references to litigation, case law, or judicial decisions. It does not cite any authorities or judicial interpretations. The instrument is a technical standard; it does not itself record administrative appeals or litigation outcomes.

Because the provided instrument is a regulatory standard made under the Therapeutic Goods Act 1989, disputes arising from its administration would generally occur within broader regulatory and judicial processes established by the Act and wider administrative law, for example review of administrative decisions by the Administrative Appeals Tribunal or judicial review in federal courts. However, the order as supplied does not document any such proceedings, nor does it identify precedent or litigation that interprets its provisions.

Practical observations about potential legal contestation, drawn strictly from the instrument’s content:

• Documentary sufficiency disputes. Section 13 requires certificates, licences or written confirmations covering a product and each manufacturing site that were current at the time the medicinal cannabis product was manufactured (s 13(3)-(4)). A common factual or legal dispute in practice could centre on whether the submitted documentation “covers the relevant medicinal cannabis product” or the sufficiency of a certificate issued by a foreign authority. The order does not define standards of proof or evidential weight for such documents; such matters would be subject to statutory interpretation and procedural rules within enforcement processes under the Act.

• Interpretation of “not modified or transformed” for cannabinoids (s 8). The order expressly excludes decarboxylation from the meaning of modification (s 8 note). Disputes could arise over whether particular processing steps constitute a prohibited transformation. The order does not set out a technical test beyond the prohibition and the decarboxylation exception.

• Microbiological acceptance criteria choice and competent authority acceptance. Section 16(d) offers the Ph Eur special provision for raw materials “for which antimicrobial pre-treatment is not feasible and for which the competent authority accepts TAMC of the raw material exceeding 1000 CFU per g or CFU per mL.” The order does not explicitly name the competent authority in that paragraph, creating a potential locus for dispute over which authority’s acceptance is required. However, elsewhere the order references the Therapeutic Goods Administration for confirmations (for example s 13(3)(f)), suggesting the TGA will be the relevant national authority for such acceptances; the order does not explicitly say so in s 16(d).

Because the instrument does not supply litigation history, practitioners needing to know whether any courts have interpreted these provisions must consult case law databases, TGA administrative determinations, tribunal records and subsequent jurisprudence arising after the instrument’s commencement. The instrument itself contains no judicial or tribunal decisions.

This section flags specific textual details and documentary or operational traps that may be overlooked if one reads the instrument only at high level. Each item references the relevant provision in the order.

1. Active-ingredient thresholds change regulatory character. Section 4(2) treats any THC at or above 1.0% (together with any corresponding acid) and other cannabinoids at or above 2.0% (together with any corresponding acid) as active ingredients “without limiting the meaning of active ingredient in subsection (1).” That means formulations hovering near those thresholds could become subject to tighter testing, labelling and registration requirements because they cross into the “active ingredient” definition used by the order. Sponsors must calculate cannabinoid percentages including corresponding acids to determine whether the thresholds are met.

2. “Not modified or transformed” is strict but decarboxylation is permitted. Section 8 prohibits chemical modification or transformation of cannabinoids, but its note carves out decarboxylation of naturally occurring acid forms. That narrow textual carve-out means other chemical conversions, purification to single cannabinoids, or synthetic derivation from non-cannabis sources will be non-compliant under this order.

3. Decontamination with ethylene oxide is banned. Section 9(b) prohibits decontamination that “make[s] use of, or otherwise contain[s], ethylene oxide.” Ethylene oxide is commonly used in sterilisation for some botanical products internationally. Suppliers using EO fumigation will be non-compliant, and sponsors importing such material must ensure alternative decontamination methods have been used.

4. Identity testing requires three methods. Section 10 requires macroscopic, microscopic and chromatographic identification of cannabis plants used in manufacture. Some producers may rely solely on chromatographic profiles or genetic testing; the order requires all three identification methods. Implementing macroscopic and microscopic (morphological) exams may require retaining and documenting botanist expertise and lab capacity.

5. Adulteration test is substance-based, not intent-based. Section 11(3) says intent does not matter in determining adulteration. Any presence of extraneous substances (other than a permitted processing aid) can be adulteration regardless of motive. Sponsors must set up supply-chain controls and testing to detect inadvertent cross-contamination.

6. Schedule 1 limits mostly apply on a dried basis. Schedule 1(1) states that, except for item 2 (foreign matter), each limit applies on a dried basis. For products expressed on a fresh-weight or extract basis, sample preparation and expression of limits must be carefully controlled to meet the dried-basis rule.

7. Country-specific manufacturing documentary pathways are complex. Section 13(3) provides different documentary criteria depending on country. For example, Canadian manufacture has two alternative pathways in s 13(3)(c)(i) and (ii) (one involves Health Canada Part 5 confirmation plus EU GMP certificate or TGA PIC/S confirmation, the other is a Drug Establishment Licence), while New Zealand has three alternative options (s 13(3)(ea)). For manufacture in countries not listed, written TGA confirmation of PIC/S conformity is required (s 13(3)(f)). Sponsors must pick the right route and ensure documentation covers the product and each manufacturing site and is current at the time of manufacture (s 13(4)); an otherwise-valid certificate that does not explicitly cover the product or the specific site will not meet the order’s requirement.

8. The TGA’s role in confirming PIC/S conformity. For countries not listed or in specific Canadian and New Zealand pathways, the order requires written confirmation from the Therapeutic Goods Administration that the site operates in accordance with PIC/S Guide to GMP (s 13(3)(c)(i)(B), (ea)(iii), (f)). The requirement therefore places an administrative burden on sponsors to obtain TGA confirmation rather than relying solely on foreign certificates.

9. Labelling specifics are prescriptive and include prefix rules. The order prescribes acceptable batch number prefixes and expiry date prefixes (s 4 definitions) and excludes “Best by” or “Best before” as acceptable expiry date prefixes. Labelling for plant preparations demands the label include the weight of the plant preparation and the minimum dry or fresh weight of plant material from which it was prepared, together with the words “minimum” (s 15(2)(g)(i)), and similar prescriptive language for plant material (s 15(2)(h)). Using non-conforming label verbiage or omitting “minimum” where required will be non-compliant.

10. Different assay ranges for different dosage forms and regulatory status. Section 12(2) prescribes assay limits of 80-120% for herbal final form, 90-110% for certain tablets/capsules not on the Register with pooled sampling, and 90-110% for other dosage forms. Registered tablets and capsules must comply with TGO 101 assay limits (s 12(2) note). Sponsors must therefore apply the correct standard for their product’s form and registration status; misclassifying the product could expose it to the wrong assay expectation.

11. Microbiological standard selection affects test methods. Section 16 allows choice among BP, Ph Eur, USP-NF, or the Ph Eur special provision, but each choice carries an associated method prescription (s 16(a)-(c)). Choosing the Ph Eur special provision introduces an additional procedural step: the competent authority must accept TAMC exceeding 1000 CFU per g in certain raw materials (s 16(d)). The order does not explicitly name the competent authority in s 16(d), creating potential ambiguity that needs clarification with the TGA.

12. Transitional date creates inventory management risks. Sections 13-16 apply only to products released for supply on or after 1 July 2023 (s 17). Sponsors with existing stock released before that date must ensure that supply dates are correctly recorded; accidental release after that date without full compliance could create non-compliance exposure.

13. The order does not itself state penalties or enforcement mechanisms. The absence of penalty specifics in the order requires sponsors to consult the Therapeutic Goods Act and Regulations to understand enforcement consequences. Relying solely on the order text for understanding enforcement risk is insufficient.

14. “Processing aid” is permitted but must not remain in the final formulation beyond trace amounts. The order defines processing aids in s 4 and expressly excludes them from being categorised as adulterants (s 11(2)), but the definition emphasises they are not intended to remain in the final formulation, which requires both process control and analytical verification.

15. The monograph incorporation clause is qualified. Section 7 applies the Ph Eur 2619 monograph “but does not apply to the extent of any inconsistency with this order.” That means where the Ph Eur and the order conflict, the order prevails; sponsors must therefore follow the order in case of divergence.

These “gotchas” create concrete compliance traps that map directly to textual clauses. Sponsors and manufacturers should embed these specific requirements into procurement, manufacturing, labelling, and regulatory documentation workflows to avoid unanticipated non-compliance.

This section sets out a practical compliance checklist aligned to the order’s requirements, with process steps and documentary evidence that sponsors and manufacturers should assemble to demonstrate conformity.

1. Determine applicability and product classification (s 6). Confirm whether the product is a medicinal cannabis product under the order and whether it falls within the exclusions in s 6(2) (export-only medicines, items in Schedule 5, or particular items in Schedule 5A subject to their conditions). Establish whether the product is herbal final form, tablet/capsule (registered or not), or another dosage form to apply the correct assay limits (s 12(2)).

2. Establish cannabinoid status and active-ingredient thresholds (s 4(2), s 8). Analyse cannabinoid content including corresponding acids to determine whether any cannabinoid meets the thresholds in s 4(2) (THC ≥ 1.0% w/w or w/v; other cannabinoids ≥ 2.0% w/w or w/v). If a cannabinoid meets these thresholds, treat it as an active ingredient for purposes of labelling, testing and any registration or notification processes described by the Act referenced in s 4(1) “stated content” paragraphs.

3. Ensure source fidelity and permitted processing (s 8). Verify that any active ingredient or other cannabinoid is derived from the cannabis plant and has not been chemically modified or transformed except for decarboxylation of natural acid forms (s 8 note). If seeking to produce a single cannabinoid isolate or chemically modify cannabinoids, do not proceed without regulatory consultation, as those processes fall outside the order’s permitted transformations.

4. Implement identity testing protocols (s 10). Put in place macroscopic, microscopic and chromatographic identification procedures for cannabis plant material used in manufacture. Document the protocols, the laboratories and analysts involved, batch-level results and retention of specimens, since these constitute primary evidence of identity.

5. Avoid ethylene oxide decontamination (s 9). Review decontamination protocols across suppliers and manufacturing sites. If any site uses ethylene oxide, replace the method with one that does not use EO and document the change and validation that the alternative method does not adversely affect product quality.

6. Put anti-adulteration controls in place (s 11). Implement supplier and in-process controls to prevent addition or substitution of extraneous materials. Define acceptable processing aids, document their use, and provide analytical evidence that they do not remain beyond trace amounts in the final formulation.

7. Prepare testing plans matching Schedule 1 and s 16. For plant material used in manufacture, test according to Schedule 1 parameters and Ph Eur methods. Ensure tests are performed on a dried basis where required (Schedule 1(1) note), except for foreign matter (item 2). For oral and inhalation dosage forms, select one of the microbiological standards in s 16 and adopt the associated test methods listed in s 16(a)-(c). If relying on the Ph Eur special provision in s 16(d), secure the competent authority acceptance for TAMC > 1000 CFU/g where applicable; clarify with the TGA which authority will assess that acceptance.

8. Meet assay limits for active ingredients (s 12(2)). Test and document assay results in representative or pooled samples per s 12(2). For herbal final form ensure average content is between 80.0% and 120.0% of stated content. For tablets/capsules not on the Register use pooled samples of no fewer than 20 tablets/capsules and ensure 90.0%-110.0%. For other dosage forms apply 90.0%-110.0%. If the product is a registered tablet or capsule, verify compliance with TGO 101 assay limits (s 12(2) note).

9. Obtain and retain GMP documentary evidence for any overseas manufacture (s 13(2)-(4)). If steps of manufacture occur outside Australia:

   • Ensure the manufacturing site operates in accordance with one or more of the listed GMP frameworks (s 13(2)), such as the PIC/S Guide to GMP, the EU directives, US 21 CFR Part 211, Canada’s GMP, South African Guide to GMP, or the New Zealand Code of GMP.

   • Obtain the specific certificates, licences or written confirmations prescribed for the country of manufacture (s 13(3)(a)-(f), (ea)). For manufacture in the UK or EU Member States obtain a valid GMP certificate issued by the MHRA or an EU licensing authority (s 13(3)(a)-(b)). For Canada follow the options in s 13(3)(c). For other countries secure written TGA confirmation of PIC/S conformity (s 13(3)(f)).

   • Verify that each certificate or confirmation “covers the relevant medicinal cannabis product” and “relates to each manufacturing site” and that it was current at time of manufacture (s 13(4)). Maintain versioned documentary records linking certificates to specific batches and manufacturing dates.

10. Implement labelling and batch/expiry controls (s 4 definitions, s 15). Ensure labels for finished products (except those extemporaneously compounded for a particular patient) include: product name; sponsor name and contact details; storage conditions; batch number with an acceptable batch number prefix; expiry date with an acceptable expiry date prefix (not “Best by” or “Best before”); name and quantity of each active ingredient with proper units; dosage form and product quantity (s 15(2) and s 4 definitions for prefixes). For plant preparations and plant material include the minimum dry or fresh weights and the word “minimum” as specified in s 15(2)(g)-(h). Ensure label text is in English, legible, visible and durable (s 15(4)). For pharmacist-extemporaneously compounded products, provide the name and quantity of each purported active ingredient (s 15(3)).

11. Address child-resistant packaging where applicable (s 14). For all products other than plant material or those falling in s 7 of TGO 95, ensure compliance with TGO 95 section 8 and sections 9 or 10 depending on whether packaging is reclosable or non-reclosable (s 14(2)). Obtain design validation documents and retention records demonstrating compliance with TGO 95 test methods and performance criteria.

12. Set up laboratory capability and data management. Ensure laboratories performing tests are competent in Ph Eur/BP/USP-NF methods referenced in Schedule 1 and s 16. Maintain chain-of-custody, raw data, method validation and certificate of analysis documents, and link test results to batch numbers and packaging labels.

13. Transitional management and stock release control (s 17). For existing inventories, document release dates to demonstrate which regulatory standard applies. Ensure that products released for supply on or after 1 July 2023 meet the s 13-16 obligations. Implement stock rotation and release controls in ERP and quality systems to avoid inadvertent distribution of non-compliant products after the transitional date.

14. Document retention and regulatory readiness. Maintain documentary evidence of supplier qualifications, certificates of analysis, GMP certificates, batch records, and label artwork approvals. Be prepared to present documentary evidence to the TGA to prove that certificates were current at the time of manufacture (s 13(4)).

15. Regulatory liaison for ambiguous cases. For ambiguous technical points,whether a process constitutes prohibited transformation under s 8, whether a processing aid remains beyond trace amounts, or whether the Ph Eur special provision in s 16(d) is applicable,engage with the TGA before finalising production or labelling strategies. For overseas manufacture in non-listed countries or reliance on PIC/S conformity, obtain written confirmation from the TGA as required by s 13(3)(f).

16. Compliance governance. Incorporate these requirements into quality systems, supplier qualification, contracts, specifications and batch release checklists. Assign responsibility for maintaining current versions of external references (Ph Eur, BP, USP-NF, PIC/S Guide to GMP and other respective documents referenced in s 13(2)) and create a process to capture updates that may affect compliance.

This checklist is a pragmatic mapping of the order’s textual duties to operational steps. Sponsors and manufacturers should document each compliance action and keep records that explicitly connect each batch and label to the tests, certificates and confirmations required under the order (see s 12, s 13 and s 15).